Last reviewed · How we verify
NCT02480088
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism
Phase 4 trial testing Ramosetron in Postoperative Nausea and Vomiting in 300 participants. Completed in 11 March 2015.
11 March 2015
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 22 September 2014 |
| Primary completion | 11 March 2015 |
| Estimated completion | 11 March 2015 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Ramosetron — full drug profile →
- Palonosetron — full drug profile →
Conditions studied
- Postoperative Nausea and Vomiting — all drugs for Postoperative Nausea and Vomiting →
Sponsor
Yonsei University
Who can join
Adults 20 to 85, any sex, with Postoperative Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Opioid-based intravenous patient-controlled analgesia (IV-PCA) offers excellent pain control, however, its use inevitably increases the incidence of postoperative nausea and vomiting (PONV). Ramosetron and palonosetron are commonly used 5-HT3 antagonists for the prevention and treatment of PONV. It is not clear which one has superior antiemetic efficacy for the prevention of PONV in patients using opioid-based IV-PCA. The antiemetic efficacy of 5HT3 antagonists may be influenced by polymorphism of ABCB1, a drug-transporter gene. This study evaluates relative antiemetic efficacy of ramosetron and palonosetron in patients using IV-PCA after spinal surgery and impact of ABCB1 polymorphism on the antiemetic efficacy of the ramosetron and palonosetron. The incidence and intensity of PONV during postoperative 48 h will be assessed. ABCB1 polymorphisms 3435C\>T and 2677G\>T/A will be evaluated in all patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, Pace NL, et al · · 2020 · cited 125× · PMID 33075160 · DOI 10.1002/14651858.cd012859.pub2
Verify or expand the search:
- PubMed search for NCT02480088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ramosetron
Trials testing the same drug.
- NCT06166615 — The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence · Phase 2, PHASE3 · unknown
- NCT04297293 — Ramosetron OD Tablet and Postdischarge Nausea and Vomiting · Phase 4 · unknown
- NCT03232125 — Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Tre · NA · completed
- NCT03278522 — Ramosetron Pre-treatment for PONV and QT Prolongation · Phase 4 · completed
- NCT02612649 — Special Drug Use Surveillance of Irribow in Female Patients · completed
Other recruiting trials for Postoperative Nausea and Vomiting
Currently open trials in the same condition.
- NCT07336160 — ERAS-Based Preoperative Nutrition and Fasting in Total Knee Arthroplasty · NA · recruiting
- NCT07242209 — Sugammadex and Menstrual Cycle in Postoperative Nausea and Vomiting · recruiting
- NCT07244575 — Association Between Preoperative Metformin Exposure and Postoperative Nausea and Vomiting in Patients Undergoing General · recruiting
- NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02480088 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 27 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02480088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing